Question to the Department of Health and Social Care:

To ask Her Majesty’s Government, following the successful Phase 1 trials combining CPHPC and the antibody –SAP for the treatment of Amyloidosis, when they expect Phase 2 trials to commence, and what resource the National Institute for Health Research is making available to University College London to support this work.

Results in the first 15 patients with systemic amyloidosis treated with a combination of CPHPC and anti-SAP antibody have been published in the New England Journal of Medicine. The phase I study is funded by GlaxoSmithKline (GSK) and the research team includes researchers at University College London (UCL) and the National Amyloidosis Centre (NAC).

The National Institute for Health Research Clinical Research Network (CRN) provides support to help the life sciences industry delivery high quality commercial contract clinical research in the national health service. If a phase II trial is developed, the CRN will work with GSK, the NAC and UCL as appropriate, to deliver the trial.